About the Hep C Eimination Tool

More than 71 million people are infected with hepatitis C virus (HCV) worldwide. In 2015, approximately 400,000 people died of complications of HCV infection. Unlike hepatitis A and B viruses, no vaccine against HCV exists. Chronic hepatitis C is a leading cause of cirrhosis, liver cancer, and death from liver disease worldwide.

The availability of direct-acting antiviral agents (DAAs) has revolutionized HCV treatment – these medicines are safe and highly efficacious, with HCV cure rates of 95–100%. As a result, HCV can be eliminated if timely treatment can be made available on a large scale. In May 2016, the World Health Assembly pledged to eliminate HCV as a public health threat by 2030, and the WHO launched a global strategy to meet the elimination targets: 90% reduction in HCV incidence compared with the baseline (2015) and 65% reduction in HCV-related deaths.

Hep C Elimination Tool aims to provide guidance on how HCV elimination targets can be achieved in a given region or country and what is the cost of eliminating HCV. Because of several changing dynamics – such as changes in drug prices, changing HCV prevalence and incidence – Hep C Elimination tool is designed to provide up-to-date information about the disease burden and the return on investment expected with scaling-up HCV treatment.


Director, MGH Institute for Technology Assessment
& Associate Professor, Harvard Medical School
Assistant Professor of Quantitative Analysis, Mississippi State Univ. College of Business
Former Research Associate
MGH Institute for Technology Assessment
Assistant Professor, College of Engineering, The Pennsylvania State University
Tiannan (Tia) Zhan, MS
Former Research Affiliate, MGH Institute for Technology Assessment
Turgay Ayer, PhD
Turgay Ayer, PhD
George Family Foundation Early Career Professor in H. Milton Stewart School of Industrial and Systems Engineering at Georgia Institute of Technology
Mary Ann (M. A.) Ladd, BS
Mary Ann (M. A.) Ladd, BS
Systems Manager, MGH Institute for Technology Assessment
Amy Puenpatom, PhD
Amy Puenpatom, PhD
Director, Center for Observational and Real-World Evidence (CORE)
Merck & Co., Inc

Visit our other sites


Jagpreet Chhatwal, PhD
MGH Inst. for Tech. Assessment
Harvard Medical School
101 Merrimac St. STE 1010
Boston, MA 02114 United States


Logo - Merck Sharp & Dohme Corp
We acknowledge the support by Merck Sharp & Dohme in the development of the Hep C Elimination Tool.

Back to top button